| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 48 | 22.0x | 17.8x | Around median | |
Growth | 32 | 1.7% | 7.1% | Bottom tier | |
Quality | 97 | — | 4.5% | Top tier | |
Safety | 33 | 2.4x | 2.6x | Bottom tier | |
Capital Return | 48 | 2.58% | 2.12% | Around median | |
Momentum | 33 | -25.0% | 2.9% | Bottom tier | |
Sentiment | 50 | 2 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
RELX operates across four segments: Risk, Scientific, Technical & Medical STM, Legal, and Exhibitions. The Risk business relies on AI-powered analytics and decision tools, as well as proprietary and contributed data, with more than 90% of its revenue coming from machine-to-machine interactions; STM sells databases, electronic references, and scientific research, Legal provides legal information and analytics platforms such as Lexis+ with Protege, while the Exhibitions segment generates revenue from a portfolio of international events.
In fiscal year 2025, revenue was $9.6 billion, gross profit was $6.4 billion, net income was $2.1 billion, and earnings per share were 1.12. This equates to a gross profit margin of approximately 66.7% and a net income margin of approximately 21.9%, compared with revenue of $9.4 billion and net income of $1.9 billion in fiscal year 2024; earnings per share also increased from 1.031 to 1.12.
In the results announced on July 23, 2026, for Q2 of fiscal year 2026, the group delivered underlying revenue growth of 7% and underlying adjusted operating profit growth of 9% in the first half, with the adjusted operating margin improving by 70 basis points to 35.5%. Risk grew by 8%, STM by 6%, Legal by 10%, and Exhibitions by 6%; adjusted net profit increased to more than £1.2 billion, adjusted earnings per share to 68.6 pence, and cash conversion to 98%.
The analyst consensus is "Buy," with an average price target of $26 and a target range of $24 to $28. However, the average target is approximately 46% below the 52-week high of $48.40 and is even below the range low of $27.57, reflecting meaningful caution despite the positive rating. The price-to-earnings ratio is unavailable in the provided data, so RELX's valuation here is based solely on analyst targets and the 52-week range.
Figures in the text are as of 2026-08-27; the live price is shown at the top of the page.
RELX announced on July 23, 2026, underlying revenue growth of 7% and adjusted operating profit growth of 9% in the first half. Adjusted earnings per share increased by 11% at constant currencies, and the adjusted operating margin improved by 70 basis points to 35.5%. The strongest momentum came from Legal, which grew by 10% with underlying adjusted operating profit up 13%, and from Risk, which grew by 8%.
RELX relies on Lexis+ with Protege, an AI-powered legal platform integrated with authoritative legal content. The platform represented approximately 90% of new sales value in Legal during fiscal year 2026 through July 23 and accounted for nearly three-quarters of renewal value. The company added features frequently, including the integration of Lex Machina to provide historical analytics that help assess cases and their potential duration. This adoption contributed to Legal's underlying growth of 10% during the first half reported for Q2 of fiscal year 2026.
LeapSpace provides an AI-powered research workspace for exploring literature, generating ideas, collaborating, analyzing funding, and drafting comparisons within a trusted environment. Its number of active users nearly doubled during the ninety days from March to June 2026, while usage grew faster than the number of users. Scopus AI continued on an adoption trajectory similar to that of Legal tools, but the decision cycle in STM is approximately 50% longer, according to management, because of the fragmented customer base. These tools helped STM achieve underlying revenue growth of 6% and adjusted operating profit growth of 8% in the first half reported for Q2 of fiscal year 2026.
Automated analysis for informational purposes only — not investment advice.
Article submission growth exceeded 20% in the first half reported for Q2 of fiscal year 2026, while the number of published articles increased by 7% across a portfolio of 3,000 journals. Management attributes strong submissions to growth in the number of researchers, global research spending, and productivity tools, with established brands potentially benefiting from concerns about research integrity. However, it does not expect submissions to remain above 20% and anticipates that growth will moderate to the low-to-mid teens over time. It also emphasizes that publication growth lagging submission growth reflects deliberate rigor in selection and quality.
The Exhibitions segment delivered underlying revenue growth of only 6% in the first half reported for Q2 of fiscal year 2026, compared with a previous sustained pace of between 7% and 8%. Underlying adjusted operating profit growth was 2% because of event timing, comparison cycles, and the rescheduling of some events to the second half. Management also noted disruption to participants traveling from or through the Middle East to events outside the region. Remaining Middle East events represent approximately 3% of segment revenue and less than 0.5% of group revenue, but they remain subject to uncertainty regarding execution and performance.
Cash conversion reached 98%, and free cash flow exceeded £1.1 billion in the first half reported for Q2 of fiscal year 2026. The company spent £103 million on two small acquisitions, paid dividends of £151 million, and completed £1.75 billion of a planned £2.25 billion share repurchase program. It increased the interim dividend by 7% to 20.9 pence per share. At the end of June 2026, net debt was £8.7 billion and leverage was 2.3 times.
